The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Bavarian Nordic
Stock and Other Ownership Interests - Bavarian Nordic

Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer.
 
James L. Gulley
Research Funding - Astellas Medivation (Inst); Bavarian Nordic (Inst); EMD Serono (Inst); NantBioScience (Inst); Pfizer (Inst)
 
Michael Borre
No Relationships to Disclose
 
Nicholas J. Vogelzang
Employment - US Oncology
Stock and Other Ownership Interests - Caris Life Sciences
Honoraria - Pfizer; UpToDate
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Caris Life Sciences; Fujifilm; Genentech/Roche; HERON; Pfizer; Tolero Pharmaceuticals
Speakers' Bureau - AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Exelixis; Genentech/Roche; Sanofi
Research Funding - Endocyte (Inst); Merck (Inst); Suzhou Kintor Pharmaceuticals (Inst); US Oncology (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bayer/Onyx; Exelixis; Genentech/Roche; Pfizer; US Oncology
 
Siobhan Ng
Travel, Accommodations, Expenses - Amgen; Astellas Oncology; GlaxoSmithKline; Novartis; Pfizer
 
Neeraj Agarwal
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Cerulean Pharma; Clovis Oncology; Eisai; EMD Serono; Exelixis; Genentech/Roche; Medivation/Astellas; Merck; Nektar; Novartis; Pfizer
Research Funding - Amgen (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Rexahn Pharmaceuticals (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Chris C. Parker
Honoraria - Advanced Accelerator Applications; Bayer; Janssen
Consulting or Advisory Role - Bayer Schering Pharma; Janssen
Research Funding - Bayer Schering Pharma (Inst)
Travel, Accommodations, Expenses - Bayer Schering Pharma; Janssen
 
David William Pook
Honoraria - Astellas Pharma; Ipsen; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme (Inst); Pfizer
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Per Rathenborg
No Relationships to Disclose
 
Thomas W. Flaig
Leadership - Aurora Oncology
Stock and Other Ownership Interests - Aurora Oncology
Honoraria - BN ImmunoTherapeutics; GTx
Consulting or Advisory Role - GTX
Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Cougar Biotechnology; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Sotio; Tokai Pharmaceuticals
Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.
Travel, Accommodations, Expenses - Bavarian Nordic; GTx
 
Joan Carles
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Johnson & Johnson; Pfizer; Sanofi
Speakers' Bureau - Bayer; Johnson & Johnson
 
Neal D. Shore
Leadership - Large Urology Group Practice Association
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Dendreon; Ferring; Genentech/Roche; Janssen Scientific Affairs; Medivation/Astellas; Myovant Sciences; Pfizer; Sanofi; Tolmar
 
Liddy Chen
No Relationships to Disclose
 
Christopher Ryan Heery
Employment - Bavarian Nordic
Leadership - Bavarian Nordic
Stock and Other Ownership Interests - Bavarian Nordic
Honoraria - MPM Capital
Consulting or Advisory Role - MPM Capital
Travel, Accommodations, Expenses - Bavarian Nordic; MPM Capital
 
Winald R. Gerritsen
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; CureVac; Janssen-Cilag; Merck Sharp & Dohme; Sanofi
Speakers' Bureau - Merck Sharp & Dohme
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Janssen-Cilag (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Sharp & Dohme
 
Frank Priou
No Relationships to Disclose
 
Philip W. Kantoff
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; Context Therapeutics; Druggablity Technologies; Placon; Seer; Tarveda Therapeutics
Consulting or Advisory Role - Bavarian Nordic; BIND Biosciences; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; Metamark Genetics; New England Research Institutes; OncoCellMDX; Progenity; Sanofi; Seer; Tarveda Therapeutics; Thermo Fisher Scientific
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Expert Testimony - Janssen
Travel, Accommodations, Expenses - Sanofi